C4 Therapeutics (CCCC) Long-Term Investments (2021 - 2026)

C4 Therapeutics' Long-Term Investments history runs 6 years deep, the most recent figure standing at $32.6 million for Q1 2026.

• On a quarterly basis, Long-Term Investments rose 66.17% year-over-year to $32.6 million in Q1 2026; TTM through Mar 2026 was $32.6 million, a 66.17% increase from a year earlier, with the FY2025 full-year figure at $48.6 million, up 117.2% from the prior year.
• Long-Term Investments slipped to $32.6 million in Q1 2026 per CCCC's latest filing, from $48.6 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $130.5 million in Q1 2022 and bottomed at $7.9 million in Q3 2025.
• The 5-year median for Long-Term Investments is $31.6 million (2024), against an average of $40.4 million.
• Across the five-year window, Long-Term Investments surged 301.53% in 2022 and tumbled 78.44% in 2023, its largest moves.
• Year by year, Long-Term Investments stood at $61.0 million in 2022, then slumped by 54.06% to $28.0 million in 2023, then dropped by 20.17% to $22.4 million in 2024, then soared by 117.2% to $48.6 million in 2025, then slumped by 32.87% to $32.6 million in 2026.
• Per Business Quant, the three latest CCCC Long-Term Investments figures stand at $32.6 million (Q1 2026), $48.6 million (Q4 2025), and $7.9 million (Q3 2025).